These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Hero M, Mäkitie O, Kröger H, Nousiainen E, Toiviainen-Salo S, Dunkel L. Horm Res; 2009; 71(5):290-7. PubMed ID: 19339794 [Abstract] [Full Text] [Related]
3. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Shulman DI, Francis GL, Palmert MR, Eugster EA, Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee. Pediatrics; 2008 Apr; 121(4):e975-83. PubMed ID: 18381525 [Abstract] [Full Text] [Related]
10. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Hero M, Wickman S, Dunkel L. Clin Endocrinol (Oxf); 2006 May; 64(5):510-3. PubMed ID: 16649968 [Abstract] [Full Text] [Related]
11. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. Hero M, Norjavaara E, Dunkel L. J Clin Endocrinol Metab; 2005 Dec; 90(12):6396-402. PubMed ID: 16189252 [Abstract] [Full Text] [Related]
13. Strategies for maximizing growth in puberty in children with short stature. Mauras N. Pediatr Clin North Am; 2011 Oct; 58(5):1167-79, x. PubMed ID: 21981954 [Abstract] [Full Text] [Related]
19. Impaired body weight and tail length gain and altered bone quality after treatment with the aromatase inhibitor exemestane in male rats. van Gool SA, Wit JM, De Schutter T, De Clerck N, Postnov AA, Kremer Hovinga S, van Doorn J, Veiga SJ, Garcia-Segura LM, Karperien M. Horm Res Paediatr; 2010 Nov 01; 73(5):376-85. PubMed ID: 20389109 [Abstract] [Full Text] [Related]